Zeda Holdings Plans $200 Mn Investment for India Expansion

To facilitate its expansion, the company aims to partner with local entities and secure regional investments.

US-based Zeda Holdings, a leader in 3D-printed orthopedic implants, is set to raise $200 million to expand its operations into India.

This significant capital infusion will be used to establish multiple fully automated manufacturing facilities in India, focusing on metal 3D printing for trauma and spine surgery implants.

Zeda Holdings is receiving advisory support from Wodehouse Capital Advisors for its entry strategy into the Indian market. To facilitate its expansion, the company aims to partner with local entities and secure regional investments.

Outlining plans CEO Shri Shetty said, "We are looking for partners and local capital. Part of the funds will be used to acquire local entities, another portion for building a local team, and the remainder for establishing factories and forming joint ventures."

The proposed facilities, each ranging from 10,000 to 20,000 square feet, will utilize advanced semiconductor device fabrication processes for metal 3D printing.This innovative approach will enable Zeda to manufacture high-quality orthopedic implants efficiently.

Zedo’s Market Presence

Zeda Holdings has a strong track record, with 52 USFDA-approved products implanted in over 32,000 patients. The company offers more than 30 trauma devices and instruments, supported by a substantial manufacturing footprint of over 150,000 square feet in the US.

In India, Zeda's focus will primarily be on trauma implants, which represent a $3 billion segment of the country's $8 billion orthopedic implants market.

"USFDA-approved implants are typically expensive, while the cheaper alternatives used locally are often imported from countries like China, the Czech Republic, and Pakistan. By manufacturing locally, we can offer USFDA-approved implants at prices comparable to these imported products," Shetty explained.

Regulatory Pathway & Market Integration

Given Zeda's existing approvals in the US and registrations in Singapore, Shetty anticipates a relatively swift registration process in India, expecting it to take around 6-8 months. This expedited timeline will facilitate quicker market entry and distribution of their advanced orthopedic solutions.

Zeda Holdings' expansion into India represents a step towards enhancing the availability of high-quality, cost-effective orthopedic implants in the region. With advanced manufacturing technology and a strategic approach to local partnerships, Zeda is poised to make a substantial impact on the Indian healthcare market.

In a similar development, TruDoc Healthcare, a virtual primary care provider in the GCC, acquired Wellthy Therapeutics, a Mumbai-based clinically validated chronic disease management platform.

This strategic move aims to redefine healthcare outcomes, quality, and patient experience in the region while signaling TruDoc's expansion into new markets, including India.